<DOC>
	<DOC>NCT01155193</DOC>
	<brief_summary>Evaluation of Respiratory Syncytial Virus (RSV) Hospitalization and the impact of risk factors on preterm infants, infants with congenital heart disease and infants with bronchopulmonary abnormality of development immunized with Synagis.</brief_summary>
	<brief_title>Prospective, Study for the Use of Palivizumab (Synagis) in High Risk Children in Germany</brief_title>
	<detailed_description>The Synagis Post-Marketing Observational Study (PMOS) will provide information: - when and where the drug is administered - how the risk factors are distributed in the investigated population - how often RSV-related hospitalization and ICU admission occur - on the compliance rate among parents of SynagisÂ® infants</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Palivizumab</mesh_term>
	<criteria>Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the Respiratory syncytial virus season Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months. Children less than 2 years of age and with hemodynamically significant congenital heart disease. Children with known hypersensitivity to Palivizumab or any component of the formulation, or other humanized monoclonal antibodies</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Children</keyword>
	<keyword>Pre-term infants</keyword>
	<keyword>Congenital heart disease</keyword>
	<keyword>Infection</keyword>
	<keyword>Respiratory syncytial virus</keyword>
</DOC>